BioLineRx Ltd. (NASDAQ: BLRX)
$0.77
+0.0561 ( +7.86% ) 543.8K
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.
Market Data
Open
$0.77
Previous close
$0.71
Volume
543.8K
Market cap
$60.75M
Day range
$0.69 - $0.78
52 week range
$0.51 - $2.53
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
6-k | Quarterly Reports | 1 | Jun 18, 2024 |
6-k | Quarterly Reports | 3 | May 30, 2024 |
6-k | Quarterly Reports | 6 | May 28, 2024 |
6-k | Quarterly Reports | 3 | May 24, 2024 |
6-k | Quarterly Reports | 3 | May 17, 2024 |
6-k | Quarterly Reports | 3 | May 06, 2024 |
6-k | Quarterly Reports | 3 | Apr 17, 2024 |
6-k | Quarterly Reports | 3 | Apr 10, 2024 |
6-k | Quarterly Reports | 9 | Apr 01, 2024 |
20-f/a | Annual reports | 103 | Mar 26, 2024 |